Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer Irradiation
Yi Yin, Rui Li, Kangling Xu, et al.
Cancer Research (2017) Vol. 77, Iss. 18, pp. 4745-4754
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

Alternative splicing in prostate cancer
Alec Paschalis, Adam Sharp, Jonathan Welti, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 11, pp. 663-675
Closed Access | Times Cited: 157
SRSF1 modulates PTPMT1 alternative splicing to regulate lung cancer cell radioresistance
Junxiu Sheng, Qingzhi Zhao, Jinyao Zhao, et al.
EBioMedicine (2018) Vol. 38, pp. 113-126
Open Access | Times Cited: 100
Supraphysiological androgens suppress prostate cancer growth through androgen receptor–mediated DNA damage
Payel Chatterjee, Michael T. Schweizer, Jared M. Lucas, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 10, pp. 4245-4260
Open Access | Times Cited: 88
Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
Katharina Lückerath, Wei Liu, Wolfgang P. Fendler, et al.
EJNMMI Research (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 73
Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications
Beshara Sheehan, Christina Guo, Antje Neeb, et al.
European Urology Focus (2021) Vol. 8, Iss. 5, pp. 1157-1168
Open Access | Times Cited: 49
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution
Jarrell Imamura, Shinjini Ganguly, Andrew Muskara, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 19
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
Evangelia E. Kounatidou, Sirintra Nakjang, Stuart McCracken, et al.
Nucleic Acids Research (2019) Vol. 47, Iss. 11, pp. 5634-5647
Open Access | Times Cited: 48
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)
Suwen Hu, Zi Hui, Frédéric Lirussi, et al.
Expert Opinion on Therapeutic Patents (2020) Vol. 31, Iss. 5, pp. 435-452
Closed Access | Times Cited: 46
DNA-PK in human malignant disorders: Mechanisms and implications for pharmacological interventions
Michaela Medová, Matúš Medo, Lusine Hovhannisyan, et al.
Pharmacology & Therapeutics (2020) Vol. 215, pp. 107617-107617
Open Access | Times Cited: 41
microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation
Maureen Labbé, Christianne Hoey, Jessica Ray, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 40
DNA Damage Repair Deficiency in Prostate Cancer
Susanne Burdak‐Rothkamm, Wael Mansour, Kai Rothkamm
Trends in cancer (2020) Vol. 6, Iss. 11, pp. 974-984
Closed Access | Times Cited: 35
A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells
Carlos M. Roggero, Lianjin Jin, Subing Cao, et al.
Oncogene (2020) Vol. 40, Iss. 6, pp. 1106-1117
Open Access | Times Cited: 33
Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value
Fan Yu, Zhenhua Liu, Yuke Chen, et al.
Advances in Therapy (2024) Vol. 41, Iss. 6, pp. 2196-2216
Open Access | Times Cited: 4
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer
Louise Kostos, Ben Tran, Arun Azad
Drugs (2024) Vol. 84, Iss. 9, pp. 1093-1109
Open Access | Times Cited: 4
The emerging regulatory interface between DNA repair and steroid hormone receptors in cancer
Bim de Klein, Nils Eickhoff, Wilbert Zwart
Trends in Molecular Medicine (2025)
Closed Access
The potential of AR-V7 as a therapeutic target
Takuma Uo, Stephen R. Plymate, Cynthia C.T. Sprenger
Expert Opinion on Therapeutic Targets (2018) Vol. 22, Iss. 3, pp. 201-216
Closed Access | Times Cited: 36
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy
Xin Chen, Christof Bernemann, Yuri Tolkach, et al.
Urologic Oncology Seminars and Original Investigations (2017) Vol. 36, Iss. 4, pp. 161.e19-161.e30
Closed Access | Times Cited: 34
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants
Carmen A. Bañuelos, Yusuke Ito, Jon K. Obst, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1991-1991
Open Access | Times Cited: 28
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Eric H. Kim, Dengfeng Cao, Nupam P. Mahajan, et al.
NAR Cancer (2020) Vol. 2, Iss. 3
Open Access | Times Cited: 28
RETRACTED ARTICLE: Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC
Boya Zhang, Mingpeng Zhang, Yanjie Yang, et al.
Oncogene (2021) Vol. 41, Iss. 3, pp. 387-399
Open Access | Times Cited: 27
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
Ugo De Giorgi, Maddalena Sansovini, Stefano Severi, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 9, pp. 1226-1232
Open Access | Times Cited: 21
Antiandrogen enzalutamide induced genetic, cellular, and hepatic damages: amelioration by triterpene Lupeol
Mohammad Afsar Khan, Deepti Singh, Homa Fatma, et al.
Drug and Chemical Toxicology (2022) Vol. 46, Iss. 2, pp. 380-391
Closed Access | Times Cited: 15
The Androgen Receptor Does Not Directly Regulate the Transcription of DNA Damage Response Genes
Sylwia Hasterok, Thomas G. Scott, Devin G. Roller, et al.
Molecular Cancer Research (2023) Vol. 21, Iss. 12, pp. 1329-1341
Open Access | Times Cited: 9
Exosomes and prostate cancer management
Virginie Vlaeminck‐Guillem
Seminars in Cancer Biology (2021) Vol. 86, pp. 101-111
Open Access | Times Cited: 19
Current and emerging approaches to noncompetitive AR inhibition
Christopher M. Riley, J Mark Elwood, Martyn C. Henry, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1701-1747
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top